[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"predictive-value-of-tests\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:predictive-value-of-tests":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":43,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100649333","prostate-cancer-risk-calculator-for-actionable-clinical-decision-making-in-nigeria-100649333",false,"NCT07733440","PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria","Clinical Risk Calculator Validation and Implementation to Optimize Prostate Cancer Early Detection in Nigeria","PROACT","Inclusion Criteria:\n\n1. Training - Eligible primary care providers (for the training surveys) will be healthcare practitioners at community-level hospitals.\n2. Supported Risk Assessment\n\n(i) Eligible key informants will be eligible primary care providers who were trained and implemented the supported risk assessment and the targeted population of patient participants who received the supported risk assessment.\n\n(ii) Eligible patient participants (for the collection of observation data) will be the target population of adult males 40 - 79 years accessing provider services.\n\nExclusion Criteria:\n\n\\-",true,"MALE","18 Years",{"count":21,"type":22},89,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is a pilot trial that builds on findings from the validation of prostate cancer risk calculators in Nigerian men. The goal of the overall study is to improve the early detection of prostate cancer in a high-risk population.\n\nThe main questions the validation study aims to answer are:\n\n1. How accurately do existing prostate cancer risk calculators identify Nigerian men with clinically significant prostate cancer?\n2. Will a new risk calculator designed for Nigerian men more accurately identify those with clinically significant prostate cancer?\n\nThe main questions the intervention study aims to answer is:\n\nWill the primary care provider-facing risk calculator be feasible and acceptable for primary care providers to implement?\n\nThe intervention trial will be piloted among participants in community-level hospitals in order to primarily assess implementation outcomes",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Prostate Cancer","Risk Assessment","Clinical Decision Support Systems","Predictive Value of Tests","Models","Algorithms","Evidence-Based Practice","Implementation Research","Community Health Services","Primary Health Care","Biomarker","Prostate Specific Antigen","Global Health","Africa","Nigeria",[44,45,46,47,48,49,50,51,52,53,54,55,41,56,57,58,59,42],"Prostate cancer","early detection","prostate cancer screening","early diagnosis","prostate specific antigen","risk calculator","risk prediction model","diagnostic accuracy","validation","prostate biopsy","primary care","implementation science","precision prevention","clinically significant prostate cancer","clinical prediction model","community oncology","NOT_YET_RECRUITING","2026-07-24",{"date":63,"type":64},"2026-07-29","ACTUAL",{"date":66,"type":22},"2029-03",{"date":68,"type":22},"2029-08",{"name":70,"class":71},"Ahmadu Bello University","OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":81,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":72},"100580871","slew-rate-as-a-predictor-for-optimal-lead-fixation-100580871","NCT06842940","Slew Rate As a Predictor for Optimal Lead Fixation","Evaluating Slew Rate As a Predictor for Optimal Lead Fixation in Transvenous Cardiac Implantable Devices: a Prospective Multicenter Study","SLEW REGISTRY","Inclusion Criteria:\n\n* Implantation of a transvenous pacemaker with active lead fixation.\n* Implantation of a transvenous implantable cardioverter-defibrillator (ICD) with active lead fixation.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Age under 18 years.\n* Implantation of a subcutaneous ICD (S-ICD).\n* Implantation of a leadless pacemaker.\n* Patients requiring a new lead position with a previously implanted pacemaker or ICD","ALL","100 Years",{"count":84,"type":22},516,"12 Months","OBSERVATIONAL","The goal of this observational study is to identify the most reliable electrical parameter measured at the time of implantation that can predict optimal lead fixation and long-term lead performance in patients undergoing transvenous pacemaker or implantable cardioverter-defibrillator (ICD) implant.\n\nThe main questions it aims to answer are:\n\n* Is there a correlation between the slew rate measured at the time of lead implantation and the sensing measured at the 12-month follow-up?\n* Is there a correlation between all electrical parameters recorded at implantation (including slew rate, current of injury, acute sensing, acute impedance, and acute pacing threshold) and the electrical parameters assessed at 12 months post-implantation (specifically chronic sensing, chronic impedance, and chronic pacing threshold)? Participants will undergo regular follow-up evaluations, with device interrogation visits scheduled at 1 and 12 months post-implantation as part of routine clinical care.",[89,90,91,31],"Defibrillators, Implantable","Electrodes, Implanted","Pacemaker, Artificial",[93,94,95,96,97,98,99],"pacemaker","implantable cardiac defibrillator","lead","slew rate","sensing","active fixation","electrical performance","RECRUITING","2025-02-20",{"date":103,"type":64},"2025-02-24",{"date":105,"type":64},"2023-02-18",{"date":107,"type":22},"2027-02-28",{"name":109,"class":71},"Paolo Pastori, MD"]